Factors of mild and moderate course of COVID-19 in non-immunized persons
- 作者: Berdiugina O.V.1
-
隶属关系:
- Research Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
- 期: 卷 28, 编号 1 (2025)
- 页面: 49-56
- 栏目: SHORT COMMUNICATIONS
- URL: https://ogarev-online.ru/1028-7221/article/view/277342
- DOI: https://doi.org/10.46235/1028-7221-16976-FOM
- ID: 277342
如何引用文章
全文:
详细
Severity of COVID-19 is known to be related to various factors. The aim of the study was to perform comparative analysis of the features associated with mild and moderate course of infection caused by the SARS-CoV-2 virus in the absence of immunization against a new coronavirus infection, and looking for opportunities of binary classification.
We performed the analysis of clinical and laboratory data of 59 medical staff members who had a mild (group No. 1), or moderate (group No. 2) forms of COVID-19. The results were analyzed using STATISTICA and GraphPad Prism programs.
We have found that the patients with moderate course of the disease were 12% older, which numerically corresponded to a difference of 5 years (p = 0.019). Males were 1.5 times more likely to have a moderate course of the disease (p = 0.000). A part of respondents used non-specific immunoprophylactic agents. It was found that the intake of cholecalciferol, riamilovir/triazaverin did not affect the severity of disease, and the usage of human recombinant interferon alpha-2b in order to prevent SARS-CoV-2 virus infection was associated with subsequent mild course of COVID-19 (p = 0.000). More severe clinical course of COVID-19 was associated with simultaneous usage of several nonspecific immunoprophylactic agents, in particular, ascorbic acid, zinc compounds, umifenovir hydrochloride monohydrate (p = 0.000). Higher body mass index was also associated with a severe course of the disease (p = 0.034).
The analysis showed that the issue of binary classification for the patients with mild and moderate COVID-19 in the absence of vaccination may be resolved (recognition accuracy is 90.9%, p < 0.0001). The risk of moderate COVID-19 in non-immunized individuals is influenced by advanced age, gender factor, increased body mass index, presence of hypertension (70% hazard increase), as well as simultaneous use of several non-specific immunoprophylactic agents to prevent infection. Presence of allergic reactions and frequency of seasonal acute respiratory viral infections do not affect the severity of COVID-19. Prophylactic usage of human recombinant IFNa-2b is associated with milder course of infection caused by the SARS-CoV-2 virus.
作者简介
O. Berdiugina
Research Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
编辑信件的主要联系方式.
Email: berolga73@rambler.ru
PhD, MD (Biology), Leading Research Associate, Laboratory of Inflammation Immunology
俄罗斯联邦, Yekaterinburg参考
- Бердюгина О.В., Гусев Е.Ю. К вопросу о взаимосвязи аносмии/дисгевзии и неспецифической иммунопрофилактики COVID-19 // Российский иммунологический журнал, 2022. Т. 25, № 2. C. 117-124. [Berdyugina O.V., Gusev E.Yu. On the relationship between anosmia/dysgeusia and nonspecific immunoprophylaxis COVID-19. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2022, Vol. 25, no. 2, pp. 117-124. (In Russ.)] doi: 10.46235/1028-7221-1109-OTR.
- Бердюгина О.В., Гусев Е.Ю. Некоторые результаты применения риамиловира (триазавирина) медработниками для профилактики и лечения COVID-19 // Российский иммунологический журнал, 2023. Т. 26, № 3. C. 223-232. [Berdiugina O.V., Gusev E.Yu. Some results of riamilovir (triazavirine) usage in medical staff for prevention and treatment of COVID-19. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2023, Vol. 26, no. 3, pp. 223-232. (In Russ.)] doi: 10.46235/1028-7221-9410-SRO.
- Бердюгина O.В., Гусев Е.Ю. Холекальциферол в роли средства неспецифической иммунопрофилактики COVID-19 // Медицинская иммунология, 2023. Т. 25, № 4. С. 823-830. [Berdiugina O.V., Gusev E.Yu. Cholecalciferol as a means of nonspecific immunoprophylaxis against COVID-19. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, Vol. 25, no. 4, pp. 823-830. (In Russ.)] doi: 10.15789/1563-0625-CAA-2849.
- Временные методические рекомендации МЗ РФ от 16.04.2020 Лекарственная терапия острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19. Версия 2. [Электронный ресурс]. Режим доступа: https://minzdrav.gov.ru/ministry/med_covid19/. [Methodological recommendations of the Ministry of Health of the Russian Federation dated April 16, 2020 Drug therapy of acute respiratory viral infections (ARVI) in outpatient practice during the COVID-19 epidemic. Version 2. [Electronic resource]. Access mode: https://minzdrav.gov.ru/ministry/med_covid19/(In Russ.)]
- Временные методические рекомендации МЗ РФ от 26.10.2023 Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 18. [Электронный ресурс]. Режим доступа: https://www.consultant.ru/document/cons_doc_LAW_347896/. [Methodological recommendations of the Ministry of Health of the Russian Federation dated October 26, 2023 Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 18. [Electronic resource]. Access mode: https://www.consultant.ru/document/cons_doc_LAW_347896/. (In Russ.)]
- Mathioudakis N., Zachiotis M., Papadakos S., Triantafyllou M., Karapanou A., Samara S., Karamanakos G., Spandidos D.A., Papalexis P., Damaskos C., Tarantinos K., Fotakopoulos G., Sklapani P., Trakas N., Sipsas N.V., Georgakopoulou V.E. Onodera’s prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID19 during the periods of alpha, delta and omicron variant predominance. Exp. Ther. Med., 2022, Vol. 24, no. 5, 675. doi: 10.3892/etm.2022.11611.
- Mongkolsucharitkul P., Surawit A., Pumeiam S., Sookrung N., Tungtrongchitr A., Phisalprapa P., Sayabovorn N., Srivanichakorn W., Washirasaksiri C., Auesomwang C., Sitasuwan T., Chaisathaphol T., Tinmanee R., Chayakulkeeree M., Phoompoung P., Tangjittipokin W., Senawong S., Sanpawitayakul G., Muangman S., Mayurasakorn K., On Behalf Of The Siriraj Population Health And Nutrition Research Sphere Group. SARS-CoV-2 antibody response against mild-to-moderate breakthrough COVID-19 in home isolation setting in Thailand. Vaccines (Basel), 2022, Vol. 10, no. 7, 1131. doi: 10.3390/vaccines10071131.
- Nirmal A.S., Venkitakrishnan R., Augustine J., Divya R., Cleetus M., Vijay A., John S. Delayed lung function testing after COVID-19 to detect persistent lung function abnormalities – The delta – COVID-19 lung function study. J. Family Med. Prim. Care, 2022, Vol. 11, no. 11, pp. 7351-7356.
- Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., Prot M., Gallais F., Gantner P., Velay A., Le Guen J., Kassis-Chikhani N., Edriss D., Belec L., Seve A., Courtellemont L., Péré H., Hocqueloux L., Fafi-Kremer S., Prazuck T., Mouquet H., Bruel T., Simon-Lorière E., Rey F.A., Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature, 2021, Vol. 596, no. 7871, pp. 276-280.
- Ucciferri C., Di Gasbarro A., Borrelli P., Di Nicola M., Vecchiet J., Falasca K. New Therapeutic Options in Mild Moderate COVID-19 Outpatients. Microorganisms, 2022, Vol. 10, no. 11, 2131. doi: 10.3390/microorganisms10112131
- Yamaguchi D., Chimed-Ochir O., Yumiya Y., Kishita E., Akita T., Tanaka J., Kubo T. Potential risk factors to COVID-19 severity: comparison of SARS-CoV-2 delta- and omicron-dominant periods. Int. J. Environ. Res. Public Health, 2024, Vol. 21, no. 3, 322. doi: 10.3390/ijerph21030322.
补充文件
